Clinical applications of FDG-probe guided surgery

Acta Chir Belg. 2012 Nov-Dec;112(6):414-8. doi: 10.1080/00015458.2012.11680864.

Abstract

Background: For a definitive diagnosis in many oncological, inflammatory and infectious diseases histological examination is required. Non-palpable lesions detected with PET/CT scanning that cannot be localized with conventional imaging methods can be localized and excised using FDG-probe guided surgery. We describe the application of FDG-probe guided surgery in 9 patients.

Methods: The application of FDG-probe guided surgery used in 9 consecutive patients with oncological and infectious diseases is described. Four hours before surgery, 3.5 MBq/Kg body weight FDG was intravenously administered after which a FDG-PET-scan was performed to confirm the FDG-avid lesion(s). The lesions with highest activity were detected with the FDG-probe and the lesions were subsequently excised and sent for histopathological examination.

Results: In all of the 9 cases the target lesion was successfully identified and subsequently removed. When multiple and/or macroscopically normal lymph nodes were found, the use of the FDG-probe allowed selection of the PET-avid lymph nodes for resection.

Conclusion: FDG-probe guided surgery is a relatively simple surgical technique to identify and excise FDG-accumulating suspicious lesions in oncological, inflammatory and infectious diseases.

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / pathology
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Lymph Nodes / surgery*
  • Lymphatic Metastasis
  • Male
  • Melanoma / diagnosis
  • Melanoma / pathology
  • Middle Aged
  • Neoplasms / diagnosis
  • Neoplasms / pathology*
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Rectal Neoplasms / diagnosis
  • Rectal Neoplasms / pathology
  • Surgery, Computer-Assisted

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18